MENS stock forecast, quote, news & analysis
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval... Show more
Why Jyong Biotech (MENS) Stock Is Down -11% in the Last 30 Days
Key Takeaways
- Jyong Biotech (MENS) shares declined about 11% over the last 30 days, falling from roughly $1.98 to $1.76.
- The pullback extends a broader multi-month downtrend, with the stock down approximately 15% over the last quarter.
- MENS is a clinical-stage, pre-revenue biotechnology company with a small market capitalization, making its shares especially sensitive to sentiment and liquidity.
- No single company-specific catalyst has been confirmed as the driver of the recent decline, which reflects limited near-term data readouts and continued operating losses.
- The company's latest reported quarterly results showed an EPS of -$0.05, underscoring the cash burn typical of a development-stage biotech.
- Its 52-week range of $1.43 to $41.20 highlights the sharp repricing MENS has experienced since its 2025 Nasdaq listing.
- For deeper analysis, explore Jyong Biotech's Price Targets, Earnings, and Forecast pages.
- Interested in automated strategies? Explore Trending AI Robots for algorithm-driven trading ideas.
Jyong Biotech (MENS) Company Overview and Market Position
Jyong Biotech Ltd. is a Taiwan-based, science-driven biotechnology company focused on developing plant-derived (botanical) therapeutics for diseases of the urinary system. The company advances a pipeline centered on Botreso (MCS-2), a candidate in Phase III clinical trials for benign prostatic hyperplasia (BPH) and related lower urinary tract symptoms; PCP, a Phase II candidate for prostate cancer; and a candidate targeting interstitial cystitis and bladder pain syndrome. Founded in 2002 and headquartered in New Taipei City, the company listed on the Nasdaq in June 2025 and operates through subsidiaries including Health Ever Bio-Tech. As a pre-revenue developer, Jyong Biotech does not yet generate product sales, and investors follow the stock primarily for the progress and eventual outcomes of its clinical programs.
Jyong Biotech (MENS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MENS shares declined approximately 11%, moving from a closing level near $1.98 to about $1.76. The move was not linear: the stock traded in the low-$2 range during early October before sliding through mid-October and settling in the mid-to-high $1 range into November.
The broader quarterly trend points in the same direction. Compared with a closing level near $2.06 in mid-August, the stock has fallen roughly 15%, continuing a steady descent from late-summer levels. This longer-term pattern suggests that the recent 30-day weakness is part of a sustained repricing rather than an isolated event.
What Drove MENS Stock Price in the Last 30 Days
The roughly 11% decline over the past month does not appear tied to a single, confirmed corporate announcement. Instead, several structural factors likely contributed to the move. As a clinical-stage, pre-revenue company, Jyong Biotech relies on trial data and financing to drive value, and the absence of a major near-term data readout has left shares vulnerable to waning sentiment.
Liquidity also plays a role. With a market capitalization around $133 million and modest daily trading volumes, MENS can experience outsized price swings on relatively small order flow. Continued operating losses—latest reported EPS was -$0.05—keep the company dependent on external capital, a dynamic that can weigh on valuations in risk-off conditions. Broader pressure on small-cap and development-stage biotechs, along with the stock's distance from its earlier post-IPO highs, further reinforced the downward bias.
What Drove MENS Stock Performance Over the Last Quarter
The last quarter's roughly 15% decline is best understood as a continuation of a longer de-rating. Since its 2025 Nasdaq debut, MENS has traded well below the upper end of its 52-week range ($1.43–$41.20), as investors have reassessed the value of a pre-revenue pipeline without immediate catalysts. Over the trailing three months, the stock trended lower from the $2.30–$2.40 area reached in late August toward the mid-$1 range, with only brief, short-lived recoveries.
This pattern reflects persistent uncertainty about clinical timelines, the company's cash runway, and a cautious backdrop for micro-cap biotech names. Until additional data or financing milestones arrive, the multi-month narrative has centered on risk management and sentiment rather than fundamental re-ratings.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of algorithmic trading strategies from a broader platform offering hundreds of AI-powered bots that trade thousands of tickers. Only the top-performing and most relevant robots are featured in this section, making it a useful starting point for investors seeking data-driven approaches. The robots vary in trading strategy, timeframe, and performance metrics, so users can compare different styles and objectives to find approaches that suit their goals. Explore Trending AI Robots to see which automated strategies are currently generating attention.
MENS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for MENS include the progress and eventual data readouts from its lead Phase III program, Botreso (MCS-2) for benign prostatic hyperplasia, as well as developments in its earlier-stage prostate cancer and interstitial cystitis candidates. Financing remains a key variable: as a pre-revenue company with negative earnings, Jyong Biotech's cash runway and any capital-raising activity could materially influence the share price. Investors should also monitor upcoming earnings reports for updates on spending and trial timelines, along with broader conditions affecting small-cap biotechnology, including interest-rate expectations and risk appetite in the sector. Regulatory interactions and any changes to clinical enrollment or endpoints are additional items to track.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MENS turns negative, indicating new downward trend
MENS saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator turned negative. In 17 of the 18 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MENS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 7 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +12.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where MENS advanced for three days, in 72 of 82 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
MENS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. MENS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology